
The records of 147 cancer patients who received at least three courses of zzso chemotherapy in the Arizona Cancer Center clinic between 1982 and 1985 were reviewed to determine the safety and tolerance of zzso administered in the zzso zzso zzso was administered at doses of zzso zzso every zzso zzso The drug was added to 400 zzso of zzso zzso was brought up to zzso volume with normal saline containing 3 g of zzso zzso and was administered zzso over 1 zzso An additional liter of normal saline was administered over approximately 1 hour in patients who received zzso doses of zzso zzso Courses were interrupted if the serum zzso was greater than zzso zzso just prior to the next scheduled zzso The median total doses of zzso per patient were zzso zzso and zzso zzso and complete plus partial response rates were zzso zzso and zzso for those patients who received zzso zzso and zzso zzso zzso zzso therapy was tolerated without evidence of zzso failure and with only moderate to severe zzso in zzso of the zzso zzso zzso zzso dropped only zzso zzso and zzso between Courses 1 and 6 in patients receiving zzso doses of zzso zzso and zzso zzso zzso We conclude that zzso doses of zzso zzso can be administered safely and with acceptable tolerance in the zzso zzso 

